x
- Home
- About Diabetes
- Services
- Diabetes Mellitus Modeling Solutions
- R&D Services for Diabetes Mellitus and Diabetic Complications
- By Drug Development Process
- About Us
- Careers
- Contact Us
Cat. No.: DIA-0230615
| Product Information | |
|---|---|
| CAS No. | 875787-07-8 |
| Chemical Name | 2-[(2-chloro-4-fluorophenyl)methyl]-3-(4-fluorophenyl)-7-(trifluoromethyl)indazole |
| Formula | C21H12ClF5N2 |
| Molecular Weight | 422.78 |
| PubChem CID | 16734800 |
| SMILES | C1=CC2=C(N(N=C2C(=C1)C(F)(F)F)CC3=C(C=C(C=C3)F)Cl)C4=CC=C(C=C4)F |
| Target | Cholesterol Metabolism |
| Product Description | LXR-623 is a novel liver X-receptor(LXR) agonist with IC50 values of 179 nM and 24 nM for LXR-α and LXR-β, respectively. It is orally bioavailable and readily passes the blood-brain barrier. |
| Format & Storage | |
|---|---|
| Purity | > 98% |
| Source | Synthetic |
| Shipping | Shipped on dry ice. |
| Storage | Store at -20 °C. |
| Solubility Overview | >40 mg/mL in DMSO |
Ace Therapeutics has a team of wellknown experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
